Scisparc Minority Interest

What does Scisparc do? SciSparc Ltd develops cannabinoid-based pharmaceuticals including THX-110 for Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for infectious diseases; and THX-160 for pain. The company monetizes through drug development programs targeting specific medical conditions, with pharmaceutical companies and research institutions as primary buyers of these development assets. The firm's revenue streams derive from licensing agreements and partnerships with biopharmaceutical entities seeking to advance cannabinoid-based therapies for unmet medical needs. SciSparc focuses on repurposing Dronabinol into multiple therapeutic applications, creating a diversified portfolio of drug candidates. Its products target neurological disorders, sleep disorders, and infectious diseases, appealing to healthcare providers and patients requiring innovative treatments. The company's business model relies on generating revenue through the sale of development-stage drug assets to larger pharmaceutical firms rather than direct patient sales. The firm's pipeline includes four distinct drug candidates, each addressing different medical conditions. THX-110 targets Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 addresses Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 targets infectious diseases; and THX-160 focuses on pain management. These assets are marketed to biopharmaceutical companies as potential additions to their therapeutic portfolios. Scisparc is one of the most popular companies on Eulerpool.